This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Xylem (XYL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 17.39% and 6.03%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Xylem (XYL) Q4 results are likely to reflect the pandemic's impacts, high costs of sales and huge investments. Product offerings, contract wins and cost-control actions are anticipated to have aided.
Pentair (PNR) Hikes Dividend, Okays New Share Buyback Program
by Zacks Equity Research
Pentair's (PNR) latest dividend hike of 5% and new share repurchase authorization reflect its solid cash position.
Xylem (XYL) Q3 Earnings Top Estimates, Q4 Organic View Weak
by Zacks Equity Research
Xylem's (XYL) Q3 earnings beat estimates, while falling year over year due to weak sales generation and a decline in margins. Organic sales in the fourth quarter are predicted to fall year over year.
Xylem (XYL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 19.23% and 4.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Industrial Stocks' Earnings Due This Week: AOS, XYL, MHVYF
by Avisekh Bhattacharjee
The market downturn due to pandemic-related issues, lower production and other headwinds are expected to have affected earnings of the majority of industrial stocks in the July-September quarter. Let's see how AOS, XYL, MHVYF are likely to have fared.
Xylem (XYL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) Q3 results are likely to reflect the adverse impacts of the pandemic on operations. Product offerings, impressive backlog and savings from cost actions are expected to have aided.
FLS vs. XYL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
FLS vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Xylem (XYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FLS vs. XYL: Which Stock Is the Better Value Option?
by Zacks Equity Research
FLS vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Stock Up 29.3% in 3 Months: What's Driving it?
by Zacks Equity Research
Xylem (XYL) stands to benefit from a solid backlog, new products, innovation, efforts to boost growth and focus on operational execution. However, its debt level remains high.
IDEX's Diversified Businesses & Buyouts to Aid Amid Pandemic
by Zacks Equity Research
IDEX's (IEX) diversified product offerings, presence in multiple markets, acquired assets and cost-saving measures might aid performances in the quarters ahead. The pandemic-led headwinds persist.
Why Is Xylem (XYL) Up 9.8% Since Last Earnings Report?
by Zacks Equity Research
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xylem Displays Bright Prospects Amid Persistent Headwinds
by Zacks Equity Research
Xylem (XYL) to gain from a solid backlog, new products, innovation, efforts to boost growth and focus on operational execution. However, the pandemic-led challenges and high debt are concerning.
LXFR vs. XYL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LXFR vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Surpasses Q2 Earnings Estimates, Provides View
by Zacks Equity Research
Xylem's (XYL) Q2 results reflect the adverse impacts of the pandemic, weak margins and forex woes. Sequential improvements are expected in organic sales and adjusted operating margin in Q3.
Xylem (XYL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 2.56% and 0.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Illinois Tool (ITW) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Illinois Tool (ITW) Q2 results are likely to reflect the pandemic impact, especially on automotive OEM businesses. Diversified businesses, enterprise strategy and cost-cutting might have aided.
Industrial Stock Q2 Earnings Due on Jul 30: SWK, XYL & More
by Avisekh Bhattacharjee
The impacts of the coronavirus outbreak, cost-related woes and other headwinds are expected to get reflected in the results of the majority of industrial stocks in Q2.
Xylem (XYL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Xylem's (XYL) Q2 results are expected to reflect the adverse impacts of the pandemic on its operations. Solid contract wins, product offerings and cost-management are likely to have been tailwinds.
5 Industrial Stocks Poised for an Earnings Beat in Q2
by Payal Jalan
Industrial product stocks are expected to reflect gains from the pandemic-led product demand, spur in e-commerce and cost-saving measures. We present five stocks poised for an earnings beat in Q2.
Xylem (XYL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Xylem (XYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FLS vs. XYL: Which Stock Is the Better Value Option?
by Zacks Equity Research
FLS vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Provides Update on Q2 results, Confirms Deal Wins
by Zacks Equity Research
Xylem (XYL) provides a financial update for second-quarter results. Also, it secures two significant contracts in the second quarter.
LXFR vs. XYL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LXFR vs. XYL: Which Stock Is the Better Value Option?